Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis

Leukemia and Lymphoma

Volumn 47, Issue 6, 2006, Pages 998-1005

  Ganjoo, Kristen ^a   An, Caroline ^b   Robertson, Michael ^b   Gordon, Leo ^c   Sen, Joy ^b   Weisenbach, Jill ^b   Li, Shuli ^d   Weller, Edie ^d   Orazi, Attilio ^b   Horning, Sandra ^a  

^a STANFORD UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Anti angiogenesis; Bevacizumab; Diffuse large B cell lymphoma; Micro vessel density; Non Hodgkin's lymphoma; Rituximab; Vascular endothelial growth factor

Indexed keywords

AMINOTRANSFERASE; BEVACIZUMAB; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 8; CD31 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VASCULOTROPIN; VASCULOTROPIN A; VINCRISTINE;

ADULT; ARTICLE; B CELL LYMPHOMA; BLEEDING; BLOOD ANALYSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SAFETY; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INFECTION; LIVER DYSFUNCTION; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEINURIA; TREATMENT OUTCOME; TUMOR VASCULARIZATION; URINALYSIS;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PREDNISONE; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE;

EID: 33746290180     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600563821     Document Type: Article

References (37)

1. Fisher, R and Gaynor, E and Dahlberg, S and Oken, M and Grogan, T and Mize, E and et al. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma N Eng J Med, 328, pp. 1002-1006.
2. Gordon, L and Harrington, D and Anderson, J and Colgan, J and Glick, J and Neiman, R and et al. (1991) Comparison of a second generation combination chematherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced non-Hodgkin's lymphoma N Eng J Med, 327, pp. 1342-1349.
3. Coiffier, B and Lepage, E and Briere, J and Herbrecht, R and Tilly, H and Bouabdallah, R and et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma N Eng J Med, 346, pp. 235-242.
4. Habermann, T and Weller, E and Morrison, V and Cassileth, P and Cohn, J and Dakhil, S and et al. (2004) Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): An update Blood, 104.
5. Pfreundschuh, M and Truemper, L and Gill, D and Osterborg, A and Pettengell, R and Trneny, M and et al. (2004) First analysis of the completed Mabthera International (Mint) trial in young patients with low-risk diffuse large B-cell lymphoma (DLBCL) Blood, 104, pp. 157.
6. Salven, P and Orpana, A and Teerenhovi, L and Joensuu, H and et al. (2000) Simultaneous elevation in the serum concentration of the angiogenic growth factors and bFGF is an independent predictor of poor prognosis in non-Hodgkin's lymphoma: A single-institution study of 200 patients Blood, 96, pp. 3712-3718.
7. Lossos, I and Alizadeh, A and Eisen, M and Chan, W and Brown, P and Botstein, D and et al. (2000) Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas Proceedings of the National Academy of Sciences (USA), 97, pp. 10209-10213.
8. Hazar, B and Paydas, S and Zorludemir, S and Sahin, B and Tuncer, I and et al. (2003) Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma Leukemia & Lymphoma, 44, pp. 2089-2093.
9. Strebel, B and Chott, A and Huber, D and Exner, M and Jager, U and Wagner, O and et al. (2004) Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas N Eng J Med, 351, pp. 250-259.
10. Masood, R and Cai, J and Zheng, T and Smith, D and Hinton, D and Gill, P and et al. (2001) Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors Blood, 98, pp. 1904-1913.
11. Wang, E and Teruya-Feldstein, J and Wu, Y and Zhu, Z and Hicklin, D and Moore, M and et al. (2004) Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo Blood, 104, pp. 2893-2902.
12. Stopeck, A and Iannone, M and Rimsza, L and Miller, T and Fisher, R and Bellamy, W and et al. (2004) Expression of VEGF, VEGF receptors, and other angiogenic markers in relapsed aggressive non-Hodgkin's lymphoma: correlative studies from the SWOG S0108 trial Blood, 104. abst 2288
13. Presta, L and Chen, H and O'Connor, S and Chisholm, V and Meng, Y and Krummen, L and et al. (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res, 57, pp. 4593-4599.
14. Ryan, A and Eppler, D and Hagler, K and Bruner, R and Thomford, P and Hall, R and et al. (1999) Preclinical safety evaluation of bevacizumab, an antiangiogenic humanized monoclonal antibody Toxicol Pathol, 27, pp. 78-86.
15. Hurwitz, H and Fehrenbacher, L and Novotny, W and Cartwright, T and Hainsworth, J and Heim, W and et al. (2004) Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for metastatic colorectal cancer N Eng J Med, 350, pp. 2335-2342.
16. Sandler, A and Gray, R and Brahmer, J and Dowlati, A and Schiller, J and Perry, M and et al. (2005) Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial E4599 Proc of ASCO. Abst# LBA4
17. Miller, K and Wang, M and Gralow, J and et al. (2005) E2100: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer Proc of ASCO.
18. Giantonio, B and Catalano, P and Meropol, N and O'Dwyer, P and Mitchell, E and Alberts, M and et al. (2005) High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 Proc of ASCO. Abst# 2
19. Weidner. (1995) Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. breast Breast Cancer Res Treat, 36, pp. 169-180.
20. Ribatti, D and Vacca, A and Marzullo, A and Nico, B and Ria, R and Roncali, L and Dammacco, F. (2000) Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas Int J Cancer, 85, pp. 171-175.
21. Cox, D.(1970) Analysis of binary data. London: Methuen and Co.
22. Kaplan, E and Meier, P. (1958) Nonparametric estimation from incomplete observations Journal of the American Statistical Association, 53, pp. 457-481.
23. Smolej, L and Andrys, C and Maisnar, V and Pour, L and Maly, J and et al. (2005) Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders Acta Medica, 48, pp. 57-58.
24. Ribas, C and Colleoni, G and Silva, M and Carregoza, M and Bordin, Jo and et al. (2004) Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma Eur J Haemotol, 73, pp. 311-317.
25. Pedersen, L and Klausen, T and Davidsen, U and Johnsen, H and et al. (2005) Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma Ann Hemat, 84, pp. 510-516.
26. Singhal, S and Mehta, J and Desikan, R and Ayers, D and Roberson, P and Eddlemon, P and et al. (1999) Antitumor activity of thalidomide in refractory multiple myeloma N Eng J Med, 341, pp. 1565.
27. Dmoszynska, A and Podhorecka, M and Manko, J and Bojarska-Junak, A and Rolinski, J and Skomra, D and et al. (2005) The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma Neoplasm, 52, pp. 175-181.
28. Zhao, W and Mourah, S and Mounier, N and Leboeuf, C and Daneshpouy, M and Legres, L and et al. (2004) Vascular endothelial growth factor- A in expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression Laboratory Investigations, 84, pp. 1512-1519.
29. Ferrara, N. (2004) Vascular endothelial growth factor: Basic science and clinical progress Endocrinol Rev, 25, pp. 581-611.
30. Dvorak, H and Detmar, M and Claffey, K and Nagy, J and Van de Water, L and Senger, D and et al. (1995) Vascular permeability factor/vascular endothelial growth factor: An important mediator of angiogenesis in malignancy and inflammation Inter Arch Allergy Immunol, 107, pp. 233-235.
31. Ho, C and Sheu, L and Li, C and et al. (2002) Immunohistochemical expression of Basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin's lymphoma Applied Immunohistochemistry and Molecular Morphology, 10, pp. 316-321.
32. Niitsu, N and Okamoto, M and Nakamine, H and Yoshino, T and Tamaru, J and Nakamura, S and et al. (2004) Simultaneous elevation of the serum concentration of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma Eur J Haematol, 68, pp. 91-100.
33. Pham, C and Roberts, T and van Bruggen, N and Melnyk, O and Mann, J and Ferrara, N and et al. (1998) Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor Cancer Invest, 16, pp. 225-230.
34. Margolin, K and Gordon, M and Holmgren, E and Gaudreault, J and Novotny, W and Fyfe, G and et al. (2001) Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data J Clin Oncol, 19, pp. 851-856.
35. Gordon, M and Margolin, K and Talpaz, M and Sledge, G, Jr and Holmgren, E and Benjamin, R and et al. (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer J Clin Oncol, 19, pp. 843-845.
36. Stopeck, A and Bellamy, W and Unger, J and Rimsza, L and Iannone, M and Fisher, R and et al. (2005) Phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin's lymphoma (NHL): Southwest Oncology Group Study S0108 Proc of ASCO. abst #6592
37. Herbst, R and Johnson, D and Mininberg, E and Carbone, D and Henderson, T and Kim, E and et al. (2005) Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small cell lung cancer J Clin Oncol, 23, pp. 1-10.